Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

Topics Economy

January 06, 2026

As of January 6, 2026, the landscape of the pharmaceutical industry has been fundamentally reshaped by Eli Lilly and Company (NYSE:LLY), which recently became the first healthcare entity to surpass a...

Harvard’s CHIEF AI: The ‘Swiss Army Knife’ of Pathology Achieving 98% Accuracy in Cancer Diagnosis

Topics Economy

January 06, 2026

In a landmark achievement for computational medicine, researchers at Harvard Medical School have developed a "generalist" artificial intelligence model that is fundamentally reshaping the landscape of...

Via TokenRing AI

Topics Artificial Intelligence

The New Standard in Oncology: Harvard’s CHIEF AI Achieves Unprecedented Accuracy in Cancer Diagnosis and Prognosis

January 02, 2026

In a landmark advancement for digital pathology, researchers at Harvard Medical School have unveiled the Clinical Histopathology Imaging Evaluation Foundation (CHIEF) model, a "generalist" artificial...

Via TokenRing AI

Topics Artificial Intelligence

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Topics Economy Intellectual Property Stocks

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Via PredictStreet

Topics Economy Lawsuit World Trade

The Year-End Biotech Chill: Adaptive Biotechnologies Braces for J.P. Morgan Crucible Amid Market Sell-Off

December 30, 2025

As the final trading days of 2025 wind down, the biotechnology sector finds itself caught in a paradoxical "bifurcated" squeeze. While the broader indices have touched record highs this year, a sharp...

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

Topics Artificial Intelligence Economy Intellectual Property

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era

Topics ETFs Intellectual Property

December 25, 2025

As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments...

Via PredictStreet

Topics Economy Government Intellectual Property

Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market

December 23, 2025

Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded...

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

December 22, 2025

From Genentech

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Via Stocktwits

Topics Government World Trade

Genentech Announces Agreement With U.S. Government

December 19, 2025

From Genentech

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer

December 10, 2025

From Genentech

Genentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas

December 08, 2025

From Genentech

This hot biotech stock could have a lot more room to run.

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

The comeback may have begun.

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗

November 18, 2025

Via Benzinga

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗

November 18, 2025

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Via Stocktwits

Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why ↗

November 18, 2025

Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.

Via Benzinga

Why Roche's Positive Test Results Sent Olema Pharma Skyrocketing 200% ↗

November 18, 2025

The companies are both working on oral selective estrogen receptor degraders, which break down the estrogen cancer cells need to grow.

Via Investor's Business Daily

Topics Government

2 No-Brainer Healthcare Stocks to Buy Now ↗

November 18, 2025

These two healthcare stocks scan as bargains right now.

Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer

November 18, 2025

From Genentech

Magnificent Seven, beware. Kai Wu says Wall Street's AI darlings are shifting toward a riskier, capital-heavy model.

Magnificent Seven Will Become Low-Profit Tech Utilities, Analyst Warns ↗

November 17, 2025

Via Benzinga

Topics Artificial Intelligence

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗

November 17, 2025

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug.

Via Investor's Business Daily

Why Roche Holding Stock Popped Today ↗

November 10, 2025

Roche is great at developing drugs -- but is its stock a great buy?

Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on rival TG Therapeutics.

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results ↗

November 10, 2025

Via Investor's Business Daily

Multimodal AI Unleashes New Era in Cancer Research: A Revolution in Diagnosis and Treatment

November 10, 2025

Recent breakthroughs in multimodal Artificial Intelligence (AI) are fundamentally reshaping the landscape of cancer research, ushering in an era of unprecedented precision in diagnosis and personalized...

Via TokenRing AI

Topics Artificial Intelligence

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

November 10, 2025

From Genentech